The first patient has been screened in the P-III study evaluating the safety & efficacy of LB1148 in ~600 adult patients undergo a scheduled bowel resection surgery incl. laparotomy or laparoscopic surgical approaches
The 1EPs of the study is a time for recovery of the upper & lower gastrointestinal tract following surgery. The trial will make use of the same dosage of LB1148 as was utilized in the P-II study which demonstrated a 1.1-day improvement in return bowel function
LB1148 is a novel oral liquid formulation of digestive enzyme inhibitor tranexamic acid to minimize abdominal adhesions & restore bowel function following surgery. The treatment is now being developed to be used before surgeries that are at risk of disrupting the intestinal epithelial barrier
Ref: GlobalNewswire | Image: Palisade Bio
